Circulating tumor DNA (ctDNA) variants hold significant promise as cancer biomarkers in liquid biopsies, owing to their minimally invasive testing approach and capacity to capture the comprehensive tu
There is a great need of non-invasive tools that inform of an early molecular response to cancer therapeutic treatment. Here, we have tested the hypothesis that proteolytically resistant proteins coul
